Class 9, Part 1: The Life Science R&D Model and National Institutes of Health (NIH)

TL;DR

Antibiotic resistance is a growing problem, but the current blockbuster drug model does not incentivize the development of new antibiotics. There is a need for new approaches, such as government subsidies or patent extensions, to encourage innovation in drug development and combat the rise of resistant bacteria.

Transcript

The following content is provided under a Creative Commons license. Your support will help MIT OpenCourseWare continue to offer high-quality educational resources for free. To make a donation or to view additional materials from hundreds of MIT courses, visit MIT OpenCourseWare at ocw.mit.edu. WILLIAM BONVILLIAN: So I try to do this at least every ... Read More

Key Insights

• 💗 Antibiotic resistance is a significant and growing problem, but the current economic model does not incentivize the development of new antibiotics.
• 👶 Government intervention, such as subsidies or guaranteed drug purchases, may be necessary to encourage companies to invest in the development of new antibiotics.

Questions & Answers

Q: Why is antibiotic resistance becoming a growing problem?

Antibiotic resistance is increasing due to the overuse and misuse of antibiotics, which has allowed bacteria to evolve and develop resistance mechanisms. Additionally, the current lack of incentives for developing new antibiotics has contributed to the problem.

Q: How could government subsidies or guaranteed drug purchases incentivize the development of new antibiotics?

By providing financial support or guaranteed markets, the government can offset the high costs of developing new antibiotics and ensure that companies have a return on their investment. This would encourage more companies to invest in research and development in this area.

Q: What challenges does the FDA face in evaluating and approving new medical products?

The FDA faces challenges in keeping up with rapidly advancing scientific discoveries, which can make the evaluation and approval process slow and inefficient. There is a need for research to improve the FDA's ability to evaluate new medical products and incorporate new scientific advancements into the approval process.

Summary & Key Takeaways

• Antibiotic resistance is on the rise, with an increasing number of infections becoming resistant to common antibiotics.

• The current blockbuster drug model does not provide sufficient incentives for companies to develop new antibiotics, as these drugs are typically used for short periods and have a low return on investment.

• The Infectious Disease Society of America suggests government subsidies or guaranteed drug purchases as a way to incentivize the development of new antibiotics.

• The FDA faces challenges in evaluating and approving new medical products, and there is a need for research to improve the efficiency and reliability of the approval process.